310.60DKK-7.56%Mkt Cap: 21.93B DKKP/E: 3.47Last update: 2026-05-13
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)3.47
P/E (Forward)38.37
PEG—
P/B1.48
P/S2.37
EV/EBITDA1.16
EV/Revenue0.85
EPS (TTM)89.39
EPS (Forward)8.09
Cash Flow & Leverage
FCF Yield19.26%
FCF Margin45.71%
Operating CF6.53B DKK
CapEx (TTM)69.07M DKK
Net Debt/EBITDA-2.07
Net Debt-14.05B DKK
Technical
SMA 50297.30 (+4.5%)
SMA 200408.93 (-24.0%)
Beta0.56
S&P 52W Chg24.23%
Avg Vol (30d)402.12K
Avg Vol (10d)558.98K
Technical Indicators
RSI (14)48.4
MACD6.3295
MACD Signal3.6788
MACD Hist.+2.6508
BB Upper346.50 DKK
BB Middle314.83 DKK
BB Lower283.17 DKK
BB Width20.12%
ATR (14)20.63 DKK
Vol Ratio (20d)1.42x
52W Range
233.5024% of range556.00
52W High556.00 DKK
52W Low233.50 DKK
Profitability
Gross Margin99.99%
EBITDA Margin73.58%
Profit Margin70.05%
Oper. Margin-1585.29%
ROE43.52%
ROA40.47%
Revenue Growth325.00%
Earnings Growth—
Balance Sheet
Debt/Equity0.03
Current Ratio37.17
Quick Ratio36.40
Book Value/Sh210.04 DKK
Cash/Share204.78 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.70.62M
Float56.74M
Insiders0.53%
Institutions51.80%
Analyst Consensus
Rating1.9 (Buy)
Target (Mean)519.07 DKK
Target Range275.00 DKK – 825.00 DKK
# Analysts15
Company
Market Cap21.93B DKK
Enterprise Value7.89B DKK
Revenue (TTM)9.24B DKK
Gross Profit9.21B DKK
Net Income (TTM)6.46B DKK
Revenue/Share131.10 DKK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees544
Last Price310.60 DKK
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—